109 results about "Viral glycoprotein" patented technology

A viral particle. The surface of the viral particle comprises a T cell activation primary signaling molecule and a T cell activation secondary signaling molecule; the envelope glycoprotein of the viral particle is subjected to a first mutation, so that the receptor binding ability of the viral glycoprotein is weakened or lost with respect to its receptor binding ability before the first mutation; and the envelope glycoprotein of the viral particle can also be subjected to a second mutation, so that the viral particle has enhanced resistance to complement-mediated inactivation or is not subjected to complement-mediated inactivation. The viral particle has improved specificity for targeted activation, stimulation and transduction of non-activated T cells, and is thus more applicable for the preparation of CAR-T cells in subjects.

The invention discloses an alternative virus infection model capable of being used for simulating human Marburg virus disease symptoms under BSL-2 as well as an establishment method and application of the alternative virus infection model, and belongs to the technical field of biology. According to the invention, firstly, a recombinant vesicular stomatitis virus (VSV-MARV / GP) for expressing Marburg virus glycoprotein is constructed, and the VSV-MARV / GP is used as an alternative virus to cause lethal infection of a narrative hamster. The pathogenicity of the VSV-MARV / GP has species specificity, age correlation, gender correlation and attack pathway dependency. After infection of VSV-MARV / GP, female narrative hamsters of 5 weeks old show weight loss, multiple organ failure, high virus load and other symptoms and develop into serious systemic diseases similar to those observed by human MARV patients, and all animals die within two to three days after infection. The model provided by the invention can be used as an effective tool for carrying out rapid preclinical evaluation on medical countermeasures of MARV under the BSL-2 condition.

Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and S1 is a stalk portion. As provided for herein, the viral particles further comprises a nucleic acid molecule encoding for a heterologous molecule of interest. As provided for herein, the heterologous molecule of interest may be a tandem CAR. Also provided for herein are compositions comprising the same, and methods of using the same.

An anti-rabies virus neutralizing antibody and preparation and a use thereof. Provided is an anti-rabies virus neutralizing antibody, comprising a heavy chain variable region SEQ ID NO. 1-SEQ ID NO. 3, a light chain variable region SEQ ID NO. 4-SEQ ID NO. 5, and GAS. The anti-rabies virus neutralizing antibody has good neutralizing activity; a high isoelectric point provides advantages in the stability of antibody formulations; a high Tm value indicates good thermal stability; strong affinity with recombinant rabies virus glycoproteins shows promise for the mass production of rabies virus neutralizing antibodies, providing technical support for the preparation of low-cost, safe, and effective rabies passive immune formulations.

The invention belongs to the field of biological medicine, and particularly relates to an artificially synthesized polypeptide P2 and application thereof in resisting herpes virus infection. According to the invention, a polypeptide P2 of key amino acid residues (77N, 80I, 82N, 84N, 85N and 129F) combined with virus glycoprotein gD in a specific targeting host cell surface receptor Nectin-1 is designed and obtained through an RFdiffusion algorithm; the polypeptide P2 can significantly inhibit PRV infection, and has no significant cytotoxicity; the polypeptide P2 can be used for remarkably down-regulating PRV UL42 protein expression and gB mRNA (messenger Ribonucleic Acid) level; based on the conservative property of Nectin-1 in a herpes virus invasion mechanism, the polypeptide P2 can also be used for inhibiting infection of other herpes viruses (such as HSV-1 and HSV-2), and an important strategy is provided for developing novel anti-herpes virus drugs.

Provided herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety wherein the targeting moiety comprises a polypeptide comprising the formula T-S1 wherein T is a target binding domain and Si is a stem moiety. The stem portion may comprise a variant Fc domain. The stem portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into viral particles to help target such particles to specific cell types. Also provided herein are compositions comprising the viral particles, and methods of use thereof.

The present invention provides a vaccine composition comprising a therapeutically effective amount of whole influenza virus, split influenza virus, virus like particle (VLP) or a combination thereof wherein one or more surface viral glycoproteins of the whole influenza virus, split influenza virus or VLP is partially glycosylated; and wherein the whole influenza virus and the split influenza virus has been attenuated or inactivated. The present invention also provides a method of preparation of the vaccine comprising the steps of injecting working virus seed with an inhibitor of the mannosidase into embryonated chicken egg to inoculate the embryonated chicken egg; incubating the inoculated embryonated chicken egg to propagate the working vims; harvesting allantonic fluids from the inoculated embryonated chicken egg; concentrating and clarifying the harvested allantonic fluids; purifying the concentrated and clarified allantonic fluids using sucrose density centrifugation; applying deglycosylation enzyme to the purified allantonic fluid to partially glycosylate viral surface glycoprotein of the propagated vims within the purified allantonic fluid; removing deglycosylation enzyme from whole vims with partially glycosylated viral surface glycoprotein; and inactivating the vims. The present invention further provides a method of treatment for prevention of influenza infection comprising the step of administering any embodiment of the vaccine of the present invention to a subject.

In aspects, the present disclosure provides a recombinant fusion protein comprising, consisting essentially of, or consisting of (a) a rhabdoviral G glycoprotein or a functional fragment or derivative thereof and (b) a targeting molecule, wherein the targeting molecule targets the recombinant fusion protein to a hematopoietic stem cell (HSC). Additional aspects are as described herein.

Provided herein are hantivirus antibodies. These hantivirus antibodies bind to the Gn and / or Gc subunits of a hantavirus glycoprotein and have broad neutralizing activity against an epitope of different hantavirus species. Such antibodies are used in methods of inducing an immune response and methods of inhibiting hantavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.

The invention relates to the field of viral vectors, in particular to a modified viral vector as well as a preparation method and application thereof. The invention discloses a modified viral vector, the surface of the modified viral vector contains viral glycoprotein, and the ability of the viral glycoprotein to bind to a ligand or receptor of the viral glycoprotein on the surface of a cell is weakened.

The present disclosure relates to viral glycoprotein variants with reduced (e.g., abolished) binding to low-density lipoprotein receptor (LDL-R) compared to a reference viral glycoprotein. Recombinant viruses pseudotyped with viral glycoprotein variants described herein and optionally an envelope surface-bound targeting molecule (e.g., an anti-CD3 scFv), methods of producing thereof, and methods of using thereof, are also provided.

The invention relates to the field of aquaculture, in particular to a preparation method and application of a recombinant live vector vaccine for infectious hematopoietic necrosis of fish. In order to solve the problem of prevention and control of the infectious hematopoietic necrosis of the fish in the aquatic product industry, a replication-defective adenovirus type 5 is selected as a target gene expression vector to construct a recombinant adenovirus vector comprising a glycoprotein gene and a nucleoprotein gene of the infectious hematopoietic necrosis virus of the fish, and a recombinant virus is obtained; the safe and effective recombinant live vector vaccine for the infectious hematopoietic necrosis of the fish is created. According to the vaccine, immunization is carried out on fishes in a soaking or bait feeding mode, the total CPM of the fishes immunized by the vaccine is 6.67%, and the total CPM of the fishes in a non-immunized control group is 94.00%. In addition, the RPS of the vaccination group fish and the RPS of the empty vector control group fish are 92.90% and 9.22% respectively. The method is at a leading level in the field of fish biological medicines at present and has remarkable creativity.

In aspects, the present disclosure provides an enveloped delivery vehicle (EDV), comprising, consisting of, consisting essentially of: (1) an envelope membrane; (2) at least one first recombinant viral membrane glycoprotein (VMG) incorporated into the envelope membrane comprising a fusion protein comprising (A) a fusogenic membrane glycoprotein (FMG) comprising a substantially intact FMG and (B) a first targeting molecule; and (3) at least one second recombinant VMG incorporated into the envelope membrane comprising a fusion protein comprising (A) a FMG comprising a substantially intact FMG and (B) a second targeting molecule; wherein the first targeting molecule and the second targeting molecule are not the same. In aspects, the present disclosure provides methods of generating EDVs described herein. In aspects, the present disclosure provides a method of improving the cell infection efficiency of an EDV as described herein. Additional aspects are as described herein.

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in anti-rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing gene fragments of the ectodomain of the G glycoprotein of the Pasteur strain rabies virus, a linker of 7 amino acids (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the gp64 baculovirus protein, with the arrangement of the sequences in the designed gene cassette being shown in figure 1.

The present disclosure provides virus-like particles (VLPs) comprising: i) a CRISPR-Cas effector polypeptide; ii) a recombinant lentivirus comprising a nucleotide sequence encoding a therapeutic polypeptide having a length of from about 250 amino acids to about 3,000 amino acids, where the VLP comprises a pseudotyping viral glycoprotein and / or a polypeptide that provides for binding to a target cell. The present disclosure provides systems for producing a VLP. The present disclosure provides methods of delivering a therapeutic protein, using a VLP of the present disclosure.

An extracellular vesicle. The surface of the extracellular vesicle comprises at least part of a viral envelope glycoprotein or a variant thereof; the at least part of the viral envelope glycoprotein or the variant thereof does not bind to a receptor or the binding to a receptor is inhibited; and the extracellular vesicle is difficult to infect a cell by binding to a glycoprotein receptor. When the extracellular vesicle is used for delivering a target protein, the targeting performance of the extracellular vesicle is significantly improved. When an extracellular vesicle membrane expresses a hydrophobic protein, the expression and purification of the hydrophobic protein are facilitated.

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.

Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain that targets the viral particle to the liver and S1 is a stalk portion. The stalk portion may comprise a variant Fc domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.

Device for the preventive blocking of neurotropic viruses in the peripheral nervous system, comprising a biochemical injection system for the localized release of a neurospecific binding molecule, a detection unit for the identification of viral particles in neuromuscular tissue, and a receptor bait structure for binding viral glycoproteins with affinity for neuronal receptors, characterized in that the device prevents retrograde axonal viral transmission without permanently impairing the conductivity of the nerve tissue.

Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a co-stimulatory molecule or an activating molecule; the present invention relates to fusion molecules, as well as vectors such as lentiviral vectors comprising the fusion molecules, cells comprising the fusion molecules, and methods of using the fusion molecules. The particle may be a lentiviral particle that displays a fusion molecule on a surface of the particle, the fusion molecule comprising: a) a CD58 extracellular domain or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) a CD80 or CD86 extracellular domain or a functional fragment thereof; and a viral glycoprotein (G protein).

The compositions and methods are described for generating an immune response to a hemorrhagic fever virus such as ebolavirus, Marburgvirus, or arenavirus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Ebolavirus (such as a member of species Zaire ebolavirus), a member of genus Marburgvirus (such as a member of species Marburg marburgvirus), or a member of genus Arenavirus (such as a member of species Lassa virus) in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and / or treat an infection caused by ebolavirus, Marburgvirus, or arenavirus.

The present invention provides a Nipah virus (NiV) vaccine composition comprising (i) a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a soluble Nipah virus glycoprotein (soluble NiV-G) fused to a human type I collagen alpha 1 (COL1A1) signal peptide, (ii) an mRNA comprising an ORF encoding a full length NiV-G, and (iii) a vaccine composition comprising (i) a messenger ribonucleic acid (mRNA) encoding an ORF encoding a full length NiV-G signal peptide. (iii) an mRNA comprising an ORF encoding a full-length Nipah virus fusion protein (full-length NiV-F) or (iv) an mRNA comprising an ORF encoding a full-length NiV-G, and an mRNA comprising an ORF encoding a full-length NiV-F, and a method of inducing an immune response against Nipah virus by administering to a subject in need thereof an effective amount of a Nipah virus vaccine composition.

Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and S1 is a stalk portion. As provided for herein, the viral particles further comprises a nucleic acid molecule encoding for a heterologous molecule of interest. As provided for herein, the heterologous molecule of interest may be a tandem CAR. Also provided for herein are compositions comprising the same, and methods of using the same.

The present disclosure provides virus-like particles (VLPs) comprising: i) a CRISPR-Cas effector polypeptide; ii) a recombinant lentivirus comprising a nucleotide sequence encoding a therapeutic polypeptide having a length of from about 250 amino acids to about 3,000 amino acids, where the VLP comprises a pseudotyping viral glycoprotein and / or a polypeptide that provides for binding to a target cell. The present disclosure provides systems for producing a VLP. The present disclosure provides methods of delivering a therapeutic protein, using a VLP of the present disclosure.

The present invention discloses a method for constructing a DNA vaccine for co-expressing Marek's disease virus glycoprotein gC and gD. It belongs to the technical field of DNA molecular vaccines. It includes: Marek's disease virus glycoprotein gC and gD genes, IL-18 gene, self-cleavage polypeptides P2A and T2A, and eukaryotic expression vectors, and provides a construction method and application. The operation method of the present invention is simple, the preparation time is short, and large-scale production can be carried out; the homologous sequence between the vector and the target gene is recombined by a recombinase, and the PCR cloned product can be directly used for recombination, and the three target genes are expressed separately; it is conducive to the processing and presentation of the product of the antigen gene in the body; it is safe and reliable, and easy to store and transport. Animal experiments show that the weight of three yellow chickens immunized with DNA vaccines increases normally, no side effects occur, and the immunized chickens produce obvious humoral immunity and cellular immune responses.

The invention relates to a preparation method and application of a probe based on wheat germ lectin. The probe is provided with a core-shell structure, and the core-shell structure is provided with a core and a shell wrapping the outer surface of the core. The core of the core-shell structure is Fe3O4 nanoparticles; the shell comprises a first cationic polymer layer, a gold nanoparticle layer, a second cationic polymer layer, a first quantum dot layer, a third cationic polymer layer, a second quantum dot layer and a wheat germ agglutinin layer which are sequentially coated from the outer surface of the core to the outside. The probe has relatively strong magnetic response capability, colorimetric signals, fluorescence signals and capability of capturing various virus glycoproteins; the MAuDQD-coated WGA-LFA method based on the probe provided by the invention is relatively wide in target detection object range, relatively high in detection sensitivity, relatively high in accuracy and relatively short in detection time.

The invention relates to a rabies virus glycoprotein-based mRNA vaccine as well as a preparation method and application thereof. The mRNA vaccine comprises: (1) an immunogen mRNA for expressing rabies virus glycoprotein, wherein the rabies virus glycoprotein is G protein, IG protein, 3G protein, 3IG protein or 3IG [delta] GC protein; and (2) a vaccine vector, wherein the vaccine vector is liposome nano-particles which can be utilized by mRNA (messenger Ribonucleic Acid). The invention also provides a preparation method of the vaccine and application of the vaccine in prevention of rabies virus infection. According to the invention, G proteins and IG proteins of rabies virus strains CTN strain, SAD strain and CVS strain are taken as immunogen basis for the first time and are optimized and combined, and the rabies virus mRNA vaccine with immunogen being G protein, IG protein, 3G protein, 3IG protein or 3IG delta GC protein and vaccine vector being liposome nanoparticles is developed.

The present invention is related to the generation and use of secreted fusogenic vesicles incorporating engineered viral glycoprotein, or engineered endogenous human fusiogenic proteins derived from human endogenous retroviruses proteins, such vesicles being generally referred to as “gectosomes.” The present invention is further related to the use of engineered gectosomes to deliver therapeutic molecules or antigens to cell and tissues in a targeted manner, as well as systems and methods for using gectosomes to screen for therapeutically relevant compounds or therapeutic antibodies.

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that may introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Provided herein are particles containing a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors such as lentiviral vectors containing the same, cells containing the same, and methods for using the same. The particle may be a lentiviral particle that displays a fusion molecule containing a) the CD58 extracellular domain or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) the CD80 or CD86 extracellular domain or a functional fragment thereof, and a viral glycoprotein (G protein) on the surface of the particle.